GSK announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback